Drawbridge Health

Executive Summary

Drawbridge Health is pioneering a new category of patient-centric blood collection devices aimed at enabling convenient, low-volume blood sampling outside traditional clinical settings. Founded in 2017 and based in Menlo Park, the company targets the growing at-home diagnostics market, addressing barriers such as needle phobia, travel burden, and limited access to lab infrastructure. Its core technology simplifies sample collection, making it feasible for routine monitoring, chronic disease management, and remote patient monitoring. By reducing the friction of blood draws, Drawbridge Health has the potential to increase diagnostic compliance and empower patients with more frequent health insights. The company operates in a competitive landscape populated by players like Tasso, Seventh Sense Biosystems, and others, but its proprietary approach to low-volume, capillary blood collection could differentiate it. While still in early development stages, Drawbridge Health's technology aligns with the broader shift toward decentralized diagnostics and personalized medicine. Success will depend on achieving regulatory clearance, establishing manufacturing scalability, and forming partnerships with diagnostic labs or pharma companies. The current lack of disclosed funding or product milestones suggests a need for caution, but the addressable market—spanning diabetes, cardiovascular, and infectious disease testing—is substantial.

Upcoming Catalysts (preview)

• Q2 2027FDA 510(k) clearance or submission for blood collection device30% success
• Q4 2026Partnership with major diagnostic lab or pharma company40% success
• Q1 2027Clinical data demonstrating equivalence to venipuncture35% success